Literature DB >> 28901012

Pharmacology of cognition: a panacea for neuropsychiatric disease?

Sarah J Bailey1, Joanna C Neill2, Paula M Moran3.   

Abstract

LINKED ARTICLES: This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh：

Year:  2017        PMID： 28901012      PMCID： PMC5595767          DOI： 10.1111/bph.13956

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  16 in total

Review 1.  The pro-cognitive mechanisms of physical exercise in people with schizophrenia.

Authors:  Joseph Firth; Jack Cotter; Rebekah Carney; Alison R Yung
Journal:  Br J Pharmacol       Date:  2017-04-20       Impact factor: 8.739

Review 2.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 3.  Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia.

Authors:  John C Talpos
Journal:  Drug Discov Today       Date:  2017-04-29       Impact factor: 7.851

Review 4.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

Review 5.  Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.

Authors:  Tobias Bast; Marie Pezze; Stephanie McGarrity
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

Review 6.  Neurosteroid biosynthesis down-regulation and changes in GABAA receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment.

Authors:  Andrea Locci; Graziano Pinna
Journal:  Br J Pharmacol       Date:  2017-06-14       Impact factor: 8.739

Review 7.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

Review 8.  Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.

Authors:  John T O'Brien; Clive Holmes; Matthew Jones; Roy Jones; Gill Livingston; Ian McKeith; Peter Mittler; Peter Passmore; Craig Ritchie; Louise Robinson; Elizabeth L Sampson; John-Paul Taylor; Alan Thomas; Alistair Burns
Journal:  J Psychopharmacol       Date:  2017-01-20       Impact factor: 4.153

Review 9.  Cross-species studies of cognition relevant to drug discovery: a translational approach.

Authors:  T W Robbins
Journal:  Br J Pharmacol       Date:  2017-05-24       Impact factor: 8.739

10.  Pharmacology of cognition: a panacea for neuropsychiatric disease?

Authors:  Sarah J Bailey; Joanna C Neill; Paula M Moran
Journal:  Br J Pharmacol       Date:  2017-10       Impact factor: 8.739
View more
  1 in total

1.  Pharmacology of cognition: a panacea for neuropsychiatric disease?

Authors:  Sarah J Bailey; Joanna C Neill; Paula M Moran
Journal:  Br J Pharmacol       Date:  2017-10       Impact factor: 8.739
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.